當(dāng)前位置：首頁 SCI期刊 SCIE期刊醫(yī)學(xué) 中科院2區(qū) JCRQ1 期刊介紹(非官網(wǎng))

International ImmunopharmacologySCIE

國際簡稱：INT IMMUNOPHARMACOL 參考譯名：國際免疫藥理學(xué)

中科院分區(qū)
2區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：1567-5769; E-ISSN：1878-1705; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：是

出版信息：: 出版地區(qū)：NETHERLANDS; 出版商：Elsevier; 出版語言：English; 出版周期：Monthly; 出版年份：2001; 研究方向：醫(yī)學(xué)-免疫學(xué)

評(píng)價(jià)信息：: 影響因子：4.8; H-index：98; CiteScore指數(shù)：8.4; SJR指數(shù)：1.167; SNIP指數(shù)：0.946

發(fā)文數(shù)據(jù)：: Gold OA文章占比：14.48%; 研究類文章占比：91.76%; 年發(fā)文量：1554; 自引率：0.0357...; 開源占比：0.0911; 出版撤稿占比：0.0010...; 出版國人文章占比：0.63; OA被引用占比：0.0372...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡介International Immunopharmacology期刊介紹

International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.

The subject material appropriate for submission includes:

? Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.

? Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.

? Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.

? Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.

? Agents that activate genes or modify transcription and translation within the immune response.

? Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.

? Production, function and regulation of cytokines and their receptors.

? Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.

期刊簡介International Immunopharmacology期刊介紹

《International Immunopharmacology》自2001出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：約2.7個(gè)月約7.5周
國際TOP期刊
醫(yī)學(xué)
IMMUNOLOGY
SCIE
中科院2區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）International Immunopharmacology Cite Score數(shù)據(jù)

CiteScore：8.4
SJR：1.167
SNIP：0.946

學(xué)科類別	分區(qū)	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmacology	Q1	60 / 313	80%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Immunology and Allergy	Q2	61 / 233	74%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Immunology	Q2	72 / 236	69%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)International Immunopharmacology 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：是

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	2區(qū)	IMMUNOLOGY 免疫學(xué) PHARMACOLOGY & PHARMACY 藥學(xué)	2區(qū) 2區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國際、國內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)International Immunopharmacology JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：IMMUNOLOGY	SCIE	Q2	51 / 181	72.1%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	50 / 354	86%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：IMMUNOLOGY	SCIE	Q1	32 / 181	82.6%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	52 / 354	85.45%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國家/地區(qū)發(fā)文量統(tǒng)計(jì)

國家/地區(qū)數(shù)量
CHINA MAINLAND1568
USA140
Iran137
India79
South Korea78
Brazil69
Japan64
Egypt30
Canada26
Saudi Arabia23

本刊中國學(xué)者近年發(fā)表論文

1、Subthreshold splenic nerve stimulation prevents myocardial Ischemia-Reperfusion injury via neuroimmunomodulation of proinflammatory factor levels
Author: Jin, Xiaoxing; Wang, Xiaofei; Sun, Ji; Tan, Wuping; Zhang, Guocheng; Han, Jiapeng; Xie, Mengjie; Zhou, Liping; Yu, Zhiyao; Xu, Tianyou; Wang, Changyi; Wang, Yueyi; Zhou, Xiaoya; Jiang, Hong

Journal: INTERNATIONAL IMMUNOPHARMACOLOGY. 2023; Vol. 114, Issue , pp. -. DOI: 10.1016/j.intimp.2022.109522
2、PIM1 attenuates renal ischemia-reperfusion injury by inhibiting ASK1-JNK/P38
Author: Luo, Yanwen; Zhu, Jiefu; Zhao, Fan; Shi, Lang; Li, Yuzhen; Wu, Xiongfei

Journal: INTERNATIONAL IMMUNOPHARMACOLOGY. 2023; Vol. 114, Issue , pp. -. DOI: 10.1016/j.intimp.2022.109563
3、Association between serum levels of 12 different cytokines and short-term efficacy of anti-PD-1 monoclonal antibody combined with chemotherapy in advanced gastric cancer
Author: Qi, Qiufeng; Peng, Yun; Zhu, Ming; Zhang, Yaping; Bao, Yanqing; Zhang, Xiaobin; Zhang, Jianqing; Liu, Yongping

Journal: INTERNATIONAL IMMUNOPHARMACOLOGY. 2023; Vol. 114, Issue , pp. -. DOI: 10.1016/j.intimp.2022.109553
4、Intralesional Bacillus Calmette-Gu?erin injections and hypo-fractionated radiation synergistically induce systemic antitumor immune responses
Author: Yang, Hanshan; Hu, Yuru; Kong, Deyi; Chen, Ping; Yang, Linglin

Journal: INTERNATIONAL IMMUNOPHARMACOLOGY. 2023; Vol. 114, Issue , pp. -. DOI: 10.1016/j.intimp.2022.109542
5、PLZF promotes the development of asthma tolerance via affecting memory phenotypes of immune cells
Author: Li, Na; Shi, Tianyun; Zhang, Meng; He, Yanchao; Feng, Jingjing; Mei, Zhoufang; Su, Xiao; Jie, Zhijun

Journal: INTERNATIONAL IMMUNOPHARMACOLOGY. 2023; Vol. 114, Issue , pp. -. DOI: 10.1016/j.intimp.2022.109559
6、Effect of inactivated COVID-19 vaccination on pregnancy outcomes following frozen-thawed embryo transfer: A retrospective cohort study
Author: Huang, Jialyu; Liu, Yiqi; Zeng, Han; Tian, Lifeng; Hu, Yina; He, Jinxia; Nie, Ling; Li, You; Fang, Zheng; Deng, Weiping; Chen, Mengyi; Zhao, Xia; Ouyang, Dongxiang; Fu, Yuqing; Lin, Jiaying; Xia, Leizhen; Wu, Qiongfang

Journal: INTERNATIONAL IMMUNOPHARMACOLOGY. 2023; Vol. 114, Issue , pp. -. DOI: 10.1016/j.intimp.2022.109552
7、KLHL21/CYLD signaling confers aggressiveness in bladder cancer through inactivating NF-KB signaling
Author: Yuan, Hongyi; Wei, Shufei; Ren, Zongtao; Li, Feng; Liu, Bin; Liu, Rui; Zhang, Xiaoyu

Journal: INTERNATIONAL IMMUNOPHARMACOLOGY. 2023; Vol. 114, Issue , pp. -. DOI: 10.1016/j.intimp.2022.109202
8、Molecular hydrogen attenuates sepsis-induced cognitive dysfunction through regulation of tau phosphorylation
Author: Qi, Bo; Song, Yu; Chen, Chen; Zhao, Lina; Ma, Wanjie; Meng, Shuqi; Zhuang, Xiaoli; Lin, Huayi; Liang, Jing; Cui, Yan; Xie, Keliang

Journal: INTERNATIONAL IMMUNOPHARMACOLOGY. 2023; Vol. 114, Issue , pp. -. DOI: 10.1016/j.intimp.2022.109603